All News
Increased CV Comorbidity in Dermatomyositis
A cohort study suggest that patients with dermatomyositis (DM) are at an increased risk for multiple comorbidities, including chronic kidney and cardiovascular disease,
Read ArticleDrug-Induced Dermatomyositis
A JAMA Dermatology systematic review of drug-induced dermatomyositis (DM) found the most commonly implicated agents include hydroxyurea, immune checkpoint inhibitors, statins and lipid-lowering agents, penicillamine, and tumor necrosis factor inhibitors.
Read Article2023 Rheumatology Year in Review
Here is my top 10 list (in no particular order) of 2023 advances, game-changers, and developments that changed, or will soon change, rheumatologic practices.
Read ArticleHormonal Status Increases RA Risk
Early menopause—before the age of 45—taking hormone replacement therapy (HRT), and having 4 or more children are among several hormonal and reproductive factors linked to a heightened risk of rheumatoid arthritis in women, finds a large long term study published in the open access journal
Read ArticleBlack, Asian, and Hispanic Military Members with OA Treated Differently
Black, Asian, and Hispanic members of the U.S. Armed Forces were far less likely than their white comrades to undergo knee replacement surgeries after being diagnosed with osteoarthritis (OA), military researchers found.
Read ArticleFlorida Approves Import of Drugs from Canada
Last Friday, the Food and Drug Administration (FDA) approved Florida’s plan to import certain prescription drugs directly from Canada. Florida is the first time a state to undertake this pathway to save money.
Read ArticleHeritability of Osteoarthritis
A Swedish study examine the genetic contribution to various rheumatic/musculoskeletal diseases (RMDs) and showed that osteoarthritis (OA) had a large heritability compared with other RMDs.
Read ArticleNew Year's Resolutions (1.5.2024)
Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.
Read ArticleEnthesitis, Synovitis, and Tenosynovitis in Psoriatic Arthritis
An ultrasound study suggests that enthesitis is associated with both synovitis and tenosynovitis in patients with Psoriatic arthritis (PsA).
Read ArticleCurcumin therapy for knee osteoarthritis
Curcumin is widely used in traditional Chinese medicine to treat arthritis and is presumed to have analgesic and antiinflammatory effects that may benefit those with osteoarthritis, particularly knee osteoarthritis (KOA).
Read ArticleDoes Weight Loss Really Work in Gout?
A clinical trial has shown that obese gout patients will benefit from diet and lowered body weight, but weight loss was not associated with beneficial effects on serum urica acid (SUA), fatigue or pain.
Read ArticleSarcopenia Linked to Smoking in Osteoarthritis
Sarcopenia commonly has been linked to aging and arthritis and contributes significantly to quality of life and outcomes, but the association between sarcopenia and OA has not been well established.
Read ArticleBiomarker Predicts Survival in Autoimmune Lung Disease
One major subgroup of patients with interstitial lung disease (ILD) arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low, researchers found.
Read ArticleBest of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?
Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.
Read ArticleStillsNow Podcast December 2023 - ACR23 Highlights
Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th.
Read ArticleBest of 2023: ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions
The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Read ArticleBest of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to halt disease progression and prevent life-threatening complications from HLH/MAS.
Read ArticleBest of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Read ArticleBest of 2023: New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
Read ArticleBest of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease
The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic calcium pyrophosphate deposition (CPPD) disease is unknown. To advance our understanding of CPPD, the American College of Rheumatology and EULAR have published validated classification criteria for symptomatic CPPD disease.
Read Article